/C O R R E C T I O N -- W. L. Gore & Associates, Inc. MPD Division/

In the news release, W.L. Gore & Associates Launches GORE® SYNECOR Intraperitoneal Biomaterial In Europe, The Middle East And South Africa, issued 22-Feb-2021 by W. L. Gore & Associates, Inc. MPD Division over PR Newswire, the second paragraph, second sentence, should read "The tri-layer hybrid material was first approved and launched in 2016 in the United States and received CE mark approval in June 2020." rather than "The tri-layer hybrid material was first approved and launched in 2016 in the United States and received CE" as incorrectly transmitted by PR Newswire. The complete, corrected release follows:

W.L. Gore & Associates Launches GORE® SYNECOR Intraperitoneal Biomaterial In Europe, The Middle East And South Africa

Patient complexity is on the rise((1) )and surgeons need a high-quality material for hernia repair in complex patients (VHWG 2).((2))

FLAGSTAFF, Ariz., Feb. 22, 2021 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced that GORE SYNECOR Intraperitoneal Biomaterial is now available in Europe, Middle East and South Africa. The device was designed to address unmet needs in complex hernia repair, providing rapid vascularity(3) and permanent strength with a low profile for single, effective hernia repair.

GORE SYNECOR Intraperitoneal Biomaterial is designed for ease of use during laparoscopic, robotic and open surgical procedures. The tri-layer hybrid material was first approved and launched in 2016 in the United States and received CE mark approval in June 2020.

"This global expansion introduces a new category of synthetic hybrid material in Europe, Middle East and South Africa for surgeons to use in complex ventral hernia repair," said David Lane, General Medical Products Business Leader at Gore.

Bringing the latest innovations to hernia repair and abdominal wall reconstruction

As pioneers in the mid-term bioabsorbable mesh category, Gore is persistent in the innovation of material solutions so that surgeons have quality material options when assessing the risk for complications in complex cases. GORE SYNECOR Intraperitoneal Biomaterial is flexible and conformable, with memory for easy unrolling, handling and optimal placement. The material absorbs bodily fluids and no pre-soaking is needed.

The unique three layers of GORE SYNECOR Intraperitoneal Biomaterial are designed to promote rapid vascularity with minimal permanent material(3) (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ).

-- Parietal Surface: Gore 3D PGA:TMC web scaffold generates high-quality tissue via rapid cellular infiltration. Vascularization is reported within seven days(3) and tissue ingrowth within one month (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ). -- Mid-Layer: Macroporous knit of dense monofilament PTFE fibers designed with a fiber diameter similar to lightweight mesh but with the strength of heavyweight mesh. -- Visceral surface: Non-porous PGA:TMC film provides intra-abdominal protection, minimizing the risk of adhesion formation to the material(4) (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ). To learn more, register to attend the Gore Complex Ventral Hernia Symposium on March 16, 2021. Register here

"I am very happy to see a new prosthetic material, with excellent clinical background and promising added-value in tissue integration under the new paradigm in minimally invasive abdominal wall reconstruction," said Dr. Salvador Morales-Conde, General Digestive Surgeon, Chief of Innovation Unit, Sevilla, Spain.

GORE SYNECOR Intraperitoneal Biomaterial is part of a portfolio of surgical devices featuring Gore's proven synthetic material, including GORE(®) BIO-A(®) Tissue Reinforcement, GORE(®) SEAMGUARD(®) Bioabsorbable Staple Line Reinforcement, GORE-TEX(®) Soft Tissue Patch and GORE(®) DUALMESH(®) Biomaterial.

For more information on GORE SYNECOR Intraperitoneal Biomaterial, visit https://www.goremedical.com/eu/products/synecorip

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006;3(11):e442. 2. Ventral Hernia Working Group, Breuing K, Butler CE, et al. Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. Surgery 2010;148(3):544-558. 3. Crawford N. Assessment of Vascularity via Micro CT in Various Patch Devices. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2016. [Final study report]. 2344TL. 4. Matthews BD. Absorbable and nonabsorbable barriers on prosthetic biomaterials for adhesion prevention after intraperitoneal placement of mesh. International Surgery 2005;90(3)Supplement:S30-S34.

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. goremedical.com

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments -- from outer space to the world's highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion. gore.com

Products listed may not be available in all markets.

GORE, GORE-TEX, Together, improving life, BIO-A, DUALMESH, SEAMGUARD, SYNECOR and designs are trademarks of W. L. Gore & Associates.

Photo - Logo -

CONTACT: Shannon Rivera, W. L. Gore & Associates, srivera@wlgore.com

Web site: https://www.goremedical.com//